Drug Discovery Market Research Reports & Industry Analysis
Drug discovery is the systematic process of identifying, designing, and developing new pharmaceutical compounds or therapies to treat specific diseases or medical conditions. This is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will yield products that achieve regulatory approval by the Food & Drug Administration (FDA). To help stakeholders navigate this complex market, MarketResearch.com offers a suite of comprehensive drug discovery reports on industries big and small.
Understanding the Drug Discovery Market
- Our compilation of reports features thousands of reports from leading research firms, allowing you to access highly targeted information.
- We provide a rich repository of data, including analysis of drug discovery market trends, forecasts, growth opportunities, and strategies.
- We also provide expert commentary on disruptive technologies and the use of artificial intelligence, machine learning, and blockchain in drug discovery.
Informed Insights: Your Path to Success
Whether you're an industry professional, a consultant, or an executive, our research collection provides credible data to help you make informed decisions that catalyze growth. For decades, we have served top pharmaceutical companies, investment banks, and consulting firms as a trusted research partner. Uncover new opportunities and stay ahead of the curve with MarketResearch.com's drug discovery industry reports.
Drug Discovery Industry Research & Market Reports
-
Global Biosimulation Market (2022 Edition) – Analysis By Component (Software, Service), Application (Drug Discovery, Pre-Clinical, Clinical), End-User, By Region, By Country: Market Insights and Forecast (2018-2028)
... Azoth Analytics in November 2022, the Global Biosimulation Market was valued at USD 3011.50 Million in the year 2021. Biosimulation helps to increase the probability of success in human clinical trials, the most expensive part ... Read More
-
Glaucoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
... than 18 million total prevalent cases of glaucoma across 16 pharmaceutical markets. There are 10 marketed leading drugs for the treatment of glaucoma, Prostaglandin analogues are generally used as a first-line treatment. The R&D activity ... Read More
-
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update'; Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) pipeline Target ... Read More
-
Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Hypertension (Cardiovascular) pipeline landscape. Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone ... Read More
-
Retinal Vein Occlusion Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Development, 2022, provides an overview of the Retinal Vein Occlusion (Ophthalmology) pipeline landscape. Retinal vein occlusion is a blockage in one of the veins returning blood flow from the retina. The retina is where images ... Read More
-
Small-Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Development, 2022, provides an overview of the Small-Cell Lung Cancer (Oncology) pipeline landscape. Small cell lung cancer (SCLC) is a fast-growing type of lung cancer. It spreads much more quickly than non-small cell lung cancer. ... Read More
-
Bullous Pemphigoid Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Bullous Pemphigoid (Dermatology) pipeline landscape. Bullous pemphigoid is a chronic, inflammatory, subepidermal, blistering disease. The disease can be fatal, particularly in patients who are debilitated. Symptoms include intense itching and ... Read More
-
Bladder Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Bladder Cancer (Oncology) pipeline landscape. Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one ... Read More
-
Neurofibromatoses Type I (Von Recklinghausen’s Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... (Von Recklinghausen’s Disease) - Drugs In Development, 2022, provides an overview of the Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders) pipeline landscape. Neurofibromatosis type 1 (NF1), also called von Recklinghausen's disease, is a rare ... Read More
-
Gaucher Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Gaucher Disease (Genetic Disorders) pipeline landscape. Gaucher disease is a rare genetic disorder occurs due to lacks an enzyme called glucocerebrosidase. Symptoms include cognitive impairment, enlarged spleen, severe swelling, lung ... Read More
-
Heart Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Development, 2022, provides an overview of the Heart Transplant Rejection (Immunology) pipeline landscape. Heart transplantation is the therapy used in various heart diseases. Heart transplant replaces an injured or diseased heart with a healthy one. ... Read More
-
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Drugs In Development, 2022, provides an overview of the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline landscape. Hereditary angioedema (HAE) is a rare inherited ... Read More
-
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... or EC 2.7.11.1) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report GMDHC22213TDB, outlays comprehensive information on the Cell ... Read More
-
Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Sodium- and chloride-dependent glycine transporter 1 is a protein encoded by the SLC6A9 gene. It terminates the action of ... Read More
-
RAF Proto Oncogene Serine, Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - RAF proto-oncogene serine/threonine-protein kinase or proto-oncogene c-RAF is an enzyme is encoded by the RAF1 gene. Once activated the cellular RAF1 protein ... Read More
-
Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Encephalopathy (Central Nervous System) pipeline landscape. Encephalopathy is a term for any diffuse disease of the brain that alters brain function or structure. Symptoms include seizures, difficulty speaking or swallowing, trembling, involuntary ... Read More
-
Globoid Cell Leukodystrophy (Krabbe Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Disease) - Drugs In Development, 2022, provides an overview of the Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) pipeline landscape. Krabbe disease also called globoid cell leukodystrophy is a degenerative disorder caused by the ... Read More
-
Keloids Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Keloids (Dermatology) pipeline landscape. Keloids are a growth of extra scar tissue where the skin has healed after an injury. Symptoms include flesh-colored, red, or pink, lumpy (nodular) or ridged, irritated from ... Read More
-
Peptic Ulcers Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Peptic Ulcers (Gastrointestinal) pipeline landscape. Peptic ulcers are open sores that develop on the inside lining of esophagus, stomach and the upper portion of small intestine. Symptoms include nausea or ... Read More
-
Short Bowel Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Development, 2022, provides an overview of the Short Bowel Syndrome (Gastrointestinal) pipeline landscape. Short bowel syndrome is a complex disease that occurs due to the physical loss or the loss of function of a portion ... Read More
-
Usher Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Usher Syndrome (Genetic Disorders) pipeline landscape. Usher syndrome is an inherited condition characterized by hearing impairment and progressive vision loss. The major symptoms of Usher syndrome are hearing loss and ... Read More
-
Graves Diseases Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Graves Diseases (Hormonal Disorders) pipeline landscape. Graves' disease is an immune system disorder that results in the overproduction of thyroid hormones (hyperthyroidism). Symptoms include anxiety, weight loss, change in menstrual ... Read More
-
Alzheimer Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update
... Regulatory Path and Key Companies, 2022 Update provides comprehensive information about the Alzheimer pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in ... Read More
-
Applying AI to Drug Discovery and Development: Issues and Challenges
... screening more efficient to de-risking and accelerating clinical trials, AI tools are commonly applied across drug discovery and development. But is AI delivering value? Which AI tools are being applied successfully? What cultural challenges remain? ... Read More
-
Dermatology CROs Market Report 2022-2032
... dynamics. It will be useful for companies that would like to expand into different industries or expand their existing operations in a new region. Reduced market time, reduced infrastructure costs, and improved operational efficiency to ... Read More
Research Assistance
